<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320630</url>
  </required_header>
  <id_info>
    <org_study_id>PUCRP201305</org_study_id>
    <nct_id>NCT02320630</nct_id>
  </id_info>
  <brief_title>Combination Therapy Prevents the Relapse of RA</brief_title>
  <official_title>Rheumatology and Immunology Department，Peking University First Hospital，China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to compare the cost effective and effect of preventing recurrence by
      different treatment of TFP and HCQ combined SSZ for remittent RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients were divided into 3groups: Group A:TFP+MTX (week0-week60) Group
      B:TFP+MTX+HCQ+SSZ(week0-week12) and then MTX+HCQ+SSZ(week13-week60) Group C:TFP+MTX
      (week0-week12) and then MTX (week13-week60)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of recurrence</measure>
    <time_frame>60 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Recurrence (Disease Attribute)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single drug group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entanercept</intervention_name>
    <description>Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCQ</intervention_name>
    <description>Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).</description>
    <arm_group_label>B</arm_group_label>
    <other_name>SSZ</other_name>
    <other_name>MTX</other_name>
    <other_name>TFP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Entanercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill 2010 EULAR/ACR RA dignose criteria

          -  Age18-70 years old

          -  Have been teated regularly for 3 months

          -  Disease duration &gt; 6months

          -  DAS28&gt;3.2

        Exclusion Criteria:

          -  Received surgical operation in 8 weeks

          -  Received other biological agent (eg. rituximab, anti-TNF agents, anti-IL6 agents)in 6
             months;

          -  Injection of steroid in 4 weeks

          -  Coexisting with other CTD except for SS

          -  With severe and not controled cardiac vescular disease, neurological disease,
             pulmonary disease (including COPD and ILD), renal disease, liver disease, endocrine
             disease and Gastric Intestinal Disease

          -  With not controled diseases including asthma, IBD and psoriasis needing oral or
             injection of steroid

          -  Active infection with T&gt;38℃. Patients need admitted into hospital or biotics injection
             in 4 weeks or need oral biotics in 2 weeks

          -  Malignant history.

          -  Serum creatinine &gt;130 µmol/L

          -  AST/ALT higher than 2 times upper level

          -  platelet count&lt;100 x 109/L，or white blood count&lt;3 x 109/L

          -  Interstitail lung disease: Chest X Ray

          -  Hands X Ray ACR radiology staging shows IV stage RA

          -  Pregnancy or planing to pregnant in 2 years or suckling period women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhuoli Zhang, Pro.</last_name>
    <phone>13901094780</phone>
    <email>zhuoli.zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology and Immunology Department,Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuoli Zhang, Pro</last_name>
      <phone>13901094780</phone>
      <email>zhuoli.zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Zhuoli Zhang</investigator_full_name>
    <investigator_title>Rheumatology and Immunology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Disease Attributes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

